FKBP prolyl isomerase family member 6 (inactive)Genealiases: FKBP36 · SPGF77
Q-omics provides the consensus-scored FKBP6 profile across patient tissues and cancer cell-line models. FKBP6 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, FKBP6 is differentially expressed in 4, with the highest sampling consensus in KIRP. Additionally, FKBP6 RNA expression shows 13,977 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRC, KIRP, and TGCT as cancer lineages where FKBP6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FKBP6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FKBP6 survival associations across molecular data types. FKBP6 RNA expression shows survival associations in the most cancer types (19), followed by mutation status (7) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FKBP6 RNA expression–survival associations across cancer types. High FKBP6 expression shows unfavorable associations in KIRC, THCA, MESO, UVM and ACC, but favorable associations in LUAD. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify KIRC as the clearest survival context for FKBP6 RNA expression.
This table summarizes FKBP6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4, while mass-spec protein shows differences in 2. The strongest signals are observed in KIRP for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for FKBP6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FKBP6 shows lower tumor expression in BRCA and higher tumor expression in KIRP, CHOL and LIHC. The KIRP box plot shows higher FKBP6 RNA expression in tumor versus normal tissue (log2 FC = +0.069, t-test p < 0.001).
This table shows molecular features associated with FKBP6 in patient tissues and cancer cell lines. In patient samples, FKBP6 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, FKBP6 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in OVARY and LUNG_SCLC.
